{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:49:42Z","timestamp":1790794182317,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12890-018-0763-9","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T03:05:30Z","timestamp":1546916730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers"],"prefix":"10.1186","volume":"19","author":[{"given":"Tracy L.","family":"Staton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Cabanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathila R.","family":"Alatsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"763_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-017-0219-4","volume":"13","author":"H Kim","year":"2017","unstructured":"Kim H, Ellis AK, Fischer D, Noseworthy M, Olivenstein R, Chapman KR, Lee J. Asthma biomarkers in the age of biologics. Allergy Asthma Clin Immunol. 2017;13:48. \n                    https:\/\/doi.org\/10.1186\/s13223-017-0219-4\n                    \n                  .","journal-title":"Allergy Asthma Clin Immunol"},{"key":"763_CR2","doi-asserted-by":"publisher","first-page":"CD010834","DOI":"10.1002\/14651858.CD010834.pub3.","volume":"9","author":"HA Farne","year":"2017","unstructured":"Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834. \n                    https:\/\/doi.org\/10.1002\/14651858.CD010834.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"763_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","volume":"70","author":"NA Hanania","year":"2015","unstructured":"Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748\u201356.","journal-title":"Thorax"},{"key":"763_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","volume":"4","author":"NA Hanania","year":"2016","unstructured":"Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781\u201396. \n                    https:\/\/doi.org\/10.1016\/S2213-2600(16)30265-X\n                    \n                  .","journal-title":"Lancet Respir Med"},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31\u201344. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)30307-5\n                    \n                  .","journal-title":"Lancet"},{"key":"763_CR6","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1804092\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"763_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9899.1000107","volume":"2","author":"IP Lewkowich","year":"2011","unstructured":"Lewkowich IP. IL-17A in asthma \u2212 a question of severity. J Clin Cell Immunol. 2011;2:1\u20137.","journal-title":"J Clin Cell Immunol"},{"key":"763_CR8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1164\/rccm.201405-0859PP","volume":"190","author":"J Chesn\u00e9","year":"2014","unstructured":"Chesn\u00e9 J, Braza F, Mahay G, Brouard S, Aronica M, Magnan A. IL-17 in severe asthma. Where do we stand? Am J Respir Crit Care Med. 2014;190:1094\u2013101. \n                    https:\/\/doi.org\/10.1164\/rccm.201405-0859PP\n                    \n                  .","journal-title":"Am J Respir Crit Care Med"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1183\/09031936.00002314","volume":"44","author":"A Lind\u00e9n","year":"2014","unstructured":"Lind\u00e9n A, Dahl\u00e9n B. Interleukin-17 cytokine signalling in patients with asthma. Eur Respir J. 2014;44:1319\u201331.","journal-title":"Eur Respir J"},{"key":"763_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jaci.2010.02.008","volume":"125","author":"AT Hastie","year":"2010","unstructured":"Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, Bleecker ER, National Heart, Lung, and Blood Institute Severe Asthma Research Program. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125:1028\u20131036.e13. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2010.02.008\n                    \n                  .","journal-title":"J Allergy Clin Immunol"},{"key":"763_CR11","doi-asserted-by":"publisher","first-page":"301ra129","DOI":"10.1126\/scitranslmed.aab3142","volume":"7","author":"DF Choy","year":"2015","unstructured":"Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E, Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med. 2015;7:301ra129.","journal-title":"Sci Transl Med"},{"key":"763_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.21037\/atm.2017.02.07","volume":"5","author":"KM Hart","year":"2017","unstructured":"Hart KM, Choy DF, Bradding P, Wynn TA, Arron JR. Accurately measuring and modeling Th2 and Th17 endotypes in severe asthma. Ann Transl Med. 2017;5:91. \n                    https:\/\/doi.org\/10.21037\/atm.2017.02.07\n                    \n                  .","journal-title":"Ann Transl Med"},{"key":"763_CR13","unstructured":"Bremer M, Choy D, Jia G, Nagarkar D, Kotwal S, Lee W, Abbas A, Cai F, Arron J, Scheerens H, Staton T. Discovery of non-invasive biomarkers of IL-17 activity from experimental models of asthma. Am J Respir Crit Care Med. 2016;193:A1424. \n                    https:\/\/www.atsjournals.org\/doi\/pdf\/10.1164\/ajrccm-conference.2016.193.1_MeetingAbstracts.A1424\n                    \n                  ."},{"key":"763_CR14","unstructured":"U.S. Food and Drug Administration. \n                    https:\/\/www.fda.gov\/downloads\/Guidances\/UCM174090.pdf\n                    \n                  . Accessed 29 Feb 2016."},{"key":"763_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","volume":"365","author":"J Corren","year":"2011","unstructured":"Corren J, Lemanske RF, Hanania NA Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088\u2013109. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1106469\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"763_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ddtec.2016.09.004","volume":"21\u201322","author":"AV Kamath","year":"2016","unstructured":"Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016;21\u201322:75\u201383. \n                    https:\/\/doi.org\/10.1016\/j.ddtec.2016.09.004\n                    \n                  .","journal-title":"Drug Discov Today Technol"},{"key":"763_CR17","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic Proteins 2007. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003946.pdf\n                    \n                  . Accessed 16 Nov 2015."},{"key":"763_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.yrtph.2009.03.012","volume":"54","author":"R Ponce","year":"2009","unstructured":"Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. Immunogenicity of biologically derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol. 2009;54:164\u201382. \n                    https:\/\/doi.org\/10.1016\/j.yrtph.2009.03.012\n                    \n                  .","journal-title":"Regul Toxicol Pharmacol"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4161\/mabs.25234","volume":"5","author":"PJ Meer van","year":"2013","unstructured":"van Meer PJ, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EH, Schellekens H. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs. 2013;5:810\u20136. \n                    https:\/\/doi.org\/10.4161\/mabs.25234\n                    \n                  .","journal-title":"MAbs"},{"key":"763_CR20","unstructured":"U.S. Food and Drug Administration. FDA Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products 2014. Available from: \n                    http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm338856.pdf\n                    \n                  . Accessed 16 Nov 2015."},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2174\/1389201023378175","volume":"3","author":"E Koren","year":"2002","unstructured":"Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002;3:349\u201360.","journal-title":"Curr Pharm Biotechnol"},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2:256\u201365.","journal-title":"MAbs"},{"key":"763_CR23","unstructured":"XOLAIR\u00ae (omalizumab) U.S. Package Insert, Genentech USA, Inc. and Novartis Pharmaceuticals Corporation (2014). Available from \n                    http:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf\n                    \n                  . Accessed 16 Nov 2015."},{"key":"763_CR24","unstructured":"NUCALA\u00ae (mepolizumab) U.S. Package Insert, GlaxoSmithKline. 2017. Available from \n                    https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL.PDF\n                    \n                  . Accessed 16 Mar 2018."},{"key":"763_CR25","unstructured":"CINQAIR\u00ae (reslizumab) U.S. Package Insert, Teva Respiratory, LLC. 2016. Available from \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf\n                    \n                  . Accessed 16 Mar 2018."},{"key":"763_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2.","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S. American association of pharmaceutical scientists. assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16:658\u201373. \n                    https:\/\/doi.org\/10.1208\/s12248-014-9599-2.","journal-title":"AAPS J"},{"key":"763_CR27","doi-asserted-by":"publisher","first-page":"e3018","DOI":"10.1371\/journal.pntd.0003018","volume":"8","author":"S Puthiyakunnon","year":"2014","unstructured":"Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, Chen X. Strongyloidiasis--an insight into its global prevalence and management. PLoS Negl Trop Dis. 2014;8:e3018. \n                    https:\/\/doi.org\/10.1371\/journal.pntd.0003018\n                    \n                  .","journal-title":"PLoS Negl Trop Dis"},{"key":"763_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4269\/ajtmh.2010.09-0332","volume":"82","author":"SA Repetto","year":"2010","unstructured":"Repetto SA, Dur\u00e1n PA, Lasala MB, Gonz\u00e1lez-Cappa SM. High rate of strongyloidosis infection, out of endemic area, in patients with eosinophilia and without risk of exogenous reinfections. Am J Trop Med Hyg. 2010;82:1088\u201393.","journal-title":"Am J Trop Med Hyg"},{"key":"763_CR29","doi-asserted-by":"publisher","unstructured":"Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, Stringer K, Abonia JP, Molkentin JD, Rothenberg ME. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 2008;1:289\u201396. doi: \n                    https:\/\/doi.org\/10.1038\/mi.2008.15\n                    \n                  .","DOI":"10.1038\/mi.2008.15"},{"key":"763_CR30","doi-asserted-by":"publisher","unstructured":"Johansson MW, Annis DS, Mosher DF. \u03b1M\u03b22 integrin-mediated adhesion and motility of IL-5\u2212stimulated eosinophils on periostin. Am J Respir Cell Mol Biol 2013;48:503\u201310. doi: \n                    https:\/\/doi.org\/10.1165\/rcmb.2012-0150OC\n                    \n                  .","DOI":"10.1165\/rcmb.2012-0150OC"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-018-0763-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-018-0763-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-018-0763-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T19:05:42Z","timestamp":1578337542000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-018-0763-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1186\/s12890-018-0763-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"28 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in full conformance with the International Conference on Harmonization (ICH) E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. The study was conducted in the United States under an Investigational New Drug (IND) application in compliance with U.S. Food and Drug Administration (FDA) regulations. The Crescent City Institutional Review Board (New Orleans, LA) granted approval for this study. All subjects and patients provided written, informed consent. This manuscript adheres to the CONSORT guidelines (\/) for the reporting of clinical trials.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors were employees of Genentech, Inc. a member of the Roche group, at the time this study was performed and own Roche stock and\/or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"5"}}